
ASTH Stock Forecast & Price Target
ASTH Analyst Ratings
Bulls say
Astrana Health is supported by strong execution in value-based care, with 3Q26 revenue of $1,023.6mm, adjusted EBITDA of $77.2mm, and gross margin expanding 190bps to 12.1%, while Care Partners remained the largest growth engine at $968.8mm, up 7.9% Y/Y. Its outlook is reinforced by favorable medical cost trend running below the ~5.2% assumption, ~82% of capitation expected in full-risk by year end, and ACO results showing $120.4mm in gross shared savings across 8 ACOs, evidence that its model can manage risk and generate savings. Management also remains conservative, narrowing FY26 guidance while leaving midpoints unchanged and continuing to reinvest in growth, which suggests further upside as Medicare strength, new payor partnerships, and higher-risk contracting flow through.
Bears say
Astrana Health is exposed to a fragile earnings profile because the bear case assumes unfavorable cost trends that compress FY27 adjusted EBITDA growth, while its model remains dependent on third-party reimbursement and a heavily regulated healthcare environment. Competitive pressure also looks meaningful, as larger and better capitalized players can expand their reach in population health and digital health, making it harder for Astrana to defend share and sustain operating momentum. The cited CVS Health ACO REACH data underscore the challenge in the broader market, where ~$3.2B in spending still produced only a 3% savings rate and an 83% quality score, highlighting how difficult it may be for Astrana to deliver consistently strong economics.
This aggregate rating is based on analysts' research of Astrana Health Inc and is not a guaranteed prediction by Public.com or investment advice.
ASTH Analyst Forecast & Price Prediction
Start investing in ASTH
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Astrana Health Inc (ASTH) Forecast
ASTH Analyst Forecast & Price Prediction
Start investing in ASTH
Order type
Buy in
Order amount
Est. shares
0 shares